Home » Stocks » HRMY

Harmony Biosciences Holdings, Inc. (HRMY)

Stock Price: $27.52 USD -0.64 (-2.26%)
Updated Apr 19, 2021 12:06 PM EDT - Market open
Market Cap 1.60B
Revenue (ttm) 159.74M
Net Income (ttm) -63.85M
Shares Out 56.89M
EPS (ttm) -2.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $27.52
Previous Close $28.15
Change ($) -0.64
Change (%) -2.26%
Day's Open 28.00
Day's Range 27.45 - 28.46
Day's Volume 18,381
52-Week Range 26.51 - 52.74

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PLYMOUTH MEETING, Pa., April 12, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative thera...

1 week ago - PRNewsWire

PLYMOUTH MEETING, Pa., April 7, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...

1 week ago - PRNewsWire

Analysts at Goldman Sachs are out with four new Buy recommendations on companies in the oil, biotech and health care businesses.

Other stocks mentioned: OVV, OSCR, INNV
3 weeks ago - 24/7 Wall Street

WAKIX® (pitolisant) Total Revenue of $160 Million for Full-Year 2020; $56 Million for Fourth Quarter 2020

3 weeks ago - GlobeNewsWire

PLYMOUTH MEETING, Pa., March 19, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative thera...

1 month ago - PRNewsWire

PLYMOUTH MEETING, Pa., March 17, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative thera...

1 month ago - PRNewsWire

PLYMOUTH MEETING, Pa., March 15, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative thera...

1 month ago - PRNewsWire

PLYMOUTH MEETING, Pa., March 4, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...

1 month ago - PRNewsWire

PLYMOUTH MEETING, Pa. and CHICAGO, Dec. 17, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innov...

4 months ago - PRNewsWire

PLYMOUTH MEETING, Pa. and CHICAGO, Dec. 15, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innov...

4 months ago - PRNewsWire

WAKIX ® (pitolisant) Total Revenue of $45.6 Million for Third Quarter of 2020

5 months ago - GlobeNewsWire

PLYMOUTH MEETING, Pa. and CHICAGO, Nov. 11, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innov...

5 months ago - PRNewsWire

PLYMOUTH MEETING, Pa. and CHICAGO, Oct. 28, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innov...

5 months ago - PRNewsWire

PLYMOUTH MEETING, Pa. and CHICAGO, Oct. 14, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innov...

6 months ago - PRNewsWire

PLYMOUTH MEETING, Pa. and CHICAGO, Aug.

7 months ago - PRNewsWire

U.S. IPO Weekly Recap: Biotechs And SPACs Ride The Summer Wave In A 4 IPO Week

Other stocks mentioned: FIIIU, KYMR, NNOX
7 months ago - Seeking Alpha

Harmony shares began trading on the Nasdaq Global Market under the ticker symbol "HRMY" on August 19, 2020.

7 months ago - PRNewsWire

Harmony Biosciences: Interesting Pharmaceutical Public Offering

7 months ago - Seeking Alpha

PLYMOUTH MEETING, Pa. and CHICAGO, Aug. 18, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patient...

8 months ago - PRNewsWire

About HRMY

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvani... [Read more...]

Industry
Biotechnology
IPO Date
Aug 19, 2020
Stock Exchange
NASDAQ
Ticker Symbol
HRMY
Full Company Profile

Financial Performance

In 2020, HRMY's revenue was $159.74 million, an increase of 2,564.59% compared to the previous year's $6.00 million. Losses were -$36.94 million, -75.69% less than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for HRMY stock is "Buy." The 12-month stock price forecast is 52.00, which is an increase of 88.99% from the latest price.

Price Target
$52.00
(88.99% upside)
Analyst Consensus: Buy